NVO
Novo Nordisk A/S
NVO has the edge over RGNX overall, supported by lower modeled downside and stronger fundamentals.
RGNX
REGENXBIO Inc.
RGNX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RGNX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Strong |
RGNX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RGNX PE Valuation
RGNX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RGNX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RGNX on earnings quality, reporting a profit while its opponent remains loss making.
RGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.21 | +$0.24 |
| Q2 2026 | -$3.79 | -$0.37 |
| Q1 2026 | -$5.60 | -$2.51 |
| Q4 2025 | -$3.76 | +$0.83 |
| Q3 2025 | -$3.45 | +$1.57 |
| Q2 2025 | -$3.42 | +$1.84 |
| Q1 2025 | -$3.09 | +$2.78 |
| Q4 2024 | -$4.59 | +$1.43 |
RGNX is still losing money, but far less than before: $3.21 per share over the past year, against $6.50 at its worst in late 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over RGNX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RGNX on profitability, with a higher operating margin.
RGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.2M | -69% |
| Q2 2026 | $108M | +406% |
| Q1 2026 | $6.4M | -93% |
| Q4 2025 | $30.3M | +43% |
| Q3 2025 | $29.7M | +23% |
| Q2 2025 | $21.4M | -4.2% |
| Q1 2025 | $89M | +470% |
| Q4 2024 | $21.2M | -4.5% |
RGNX's revenue has slid since its 2021 peak: $9M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -388% | -212 points |
| Q2 2026 | 27% | +323 points |
| Q1 2026 | -1304% | -1318 points |
| Q4 2025 | -190% | +52 points |
| Q3 2025 | -176% | +80 points |
| Q2 2025 | -296% | -45 points |
| Q1 2025 | 14% | +422 points |
| Q4 2024 | -242% | +46 points |
RGNX's operating margin was −388% last quarter, down 212 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RGNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
RGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +$94.9M |
| Q2 2026 | -$63M | -$13.3M |
| Q1 2026 | -$77.4M | -337% |
| Q4 2025 | -$52.8M | -$20.1M |
| Q3 2025 | -$56.5M | -$15.6M |
| Q2 2025 | -$49.7M | -$3.8M |
| Q1 2025 | $32.6M | +$88.6M |
| Q4 2024 | -$32.7M | +$9.2M |
RGNX has burned cash in almost every quarter: −$155M over the past year, against −$106M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RGNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +12.2M shares |
| 1 year | +26% | +13.6M shares |
| 3 years | +51% | +22.1M shares |
| 5 years | +76% | +28.2M shares |
RGNX has 65M diluted shares, up 26% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RGNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -1.0x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -1.3x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
RGNX has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 20.6 | Neutral |
RGNX's weekly RSI is 47 (neutral) and its Stochastic is 21 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RGNX PE vs Healthcare Sector
| Metric | RGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGNX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.42 | 8.2% above |
| 20 week MA | $9.16 | 12% below |
| 50 week MA | $9.59 | 16% below |
| 100 week MA | $9.22 | 13% below |
| 200 week MA | $12.9 | 38% below |
RGNX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 38% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over RGNX on returns for 2026, with the stronger performance.
RGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $48.7 | +20% |
| 2021 | $48.7 | $34.8 | -29% |
| 2022 | $34.8 | $22.3 | -36% |
| 2023 | $22.3 | $18.0 | -19% |
| 2024 | $18.0 | $7.41 | -59% |
| 2025 | $7.41 | $14.2 | +91% |
| 2026 YTD | $14.2 | $8.03 | -43% |
RGNX has finished lower in four of the last six years. It's down 43% so far in 2026.